Celestra Health Lands First Major Contract with Global Pharmaceutical Firm

April 10, 2025

CELESTRA HEALTH SYSTEMS — Leader in AI-based monitoring of neurological conditions
celestrahealth.com

Celestra Health Systems is an award-winning healthcare technology company that has developed a cost-effective and highly sensitive neurological digital biomarker for unobtrusively measuring patient walking quality, under real-world conditions, at 1/100 the cost of conventional solutions.

Celestra Health has achieved several notable accomplishments this quarter, including our first major contract with a global pharmaceutical firm, the expansion of our clinical trial activities and the submission of our third round of patent applications. We are pleased with our progress this quarter and with the high levels of interest we are seeing from our target customer segments.

We signed our first major contract with a global pharmaceutical firm, valued at over $500K, for a large-scale clinical trial starting next month. In support of this activity, we have now established a logistics hub in the US.

Our Multiple Sclerosis (MS) clinical trials in the US, UK and Germany are progressing well, with excellent results. In parallel, we are finalizing preparations for the upcoming launches of 12-month clinical trials for Parkinson’s Disease and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

We submitted our third round of patent applications to the United States Patent and Trademark Office (USPTO), as well as the European Patent Office (EPO). Our patent filings, along with our significant investment in building out the world’s largest database of patient walking data (for training our AI gait algorithms), serves to fortify our competitive advantage.

In February, we were invited to present at the Ontario Biosciences Innovation Organization (OBIO) Investor Forum in Toronto, with significant levels of interest from the investment community. We are planning to close a funding round by the end of 2025.

We have specific objectives for the next quarter, including the launch of new clinical trials in the US and Canada that will serve to expand our footprint to neurological conditions beyond MS. We continue to ramp up our business development activities in the US and UK, as we launch beta pilots with leading MS neurology clinics. As part of our collaboration with the Technical University of Dresden (TUD) in Germany, we expect to complete the data collection phase of our clinical trial. This data is being used to develop and validate our In-Clinic gait measurement tool that will be eligible for reimbursement by healthcare insurance providers in Germany and beyond. Celestra Health will also be participating at the upcoming Consortium of Multiple Sclerosis Centers (CMSC) conference in Phoenix, AZ on May 28 to 31.

To learn more, please visit celestrahealth.com.